Category Archives: BioUtah News
Utah Legislative Recap – February 15, 2024
Utah Legislative Recap – Updated February 15, 2024
Centers for Medicare & Medicaid Services Publishes Draft Local Coverage Determination for KidneyIntelX and kidneyintelX.dkd
LONDON and SALT LAKE CITY, February 9, 2024 – Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces that on February 8, 2024 the Centers for Medicare and Medicaid Services (“CMS”) published a draft Local Coverage Determination (“LCD”) for the Company’s KidneyIntelX and kidneyintelX.dkd testing. The draft LCD can be accessed at https://www.cms.gov/medicare-coverage-database/. The established Medicare price […]
Utah Legislative Recap, Feb. 9, 2024
Funding Requests Life Sciences Initiative – Senator Ann Millner The original initiative requested the legislature provide $7.125M of ongoing funding to higher education in Utah to support the workforce needs of Utah’s Life Sciences industry. BioUtah has worked closely with Talent Ready Utah, colleges and universities in the state, and other stakeholders to create […]
2024 Life Sciences Day on the Hill Recap
Utah’s vibrant life sciences industry was on full display February 7 as part of BioUtah’s “Life Sciences Day on the Hill”. The event, a collarboration with the Governor’s Office of Economic Opportunity, (GOEO) was held at the state capitol. 29 companies exhibited their innovative technologies in the capitol rotunda, which provided legislators the opportunity to […]
Eris Biotech accepted to Y Combinator
Eris Biotech accepted to Y Combinator
Clene Inc. Reports ‘Unprecedented,’ Statistically Significant Long-Term Clinical Improvements for VISIONARY-MS Trial Participants with Stable Relapsing-Remitting MS
Clene Inc. (NASDAQ: CLNN) Reports ‘Unprecedented,’ Statistically Significant Long-Term Clinical Improvements for VISIONARY-MS Trial Participants with Stable Relapsing-Remitting MS
Edwards’ EVOQUE Valve Replacement System First Transcatheter Therapy to Earn FDA Approval for Tricuspid Valve
Edwards’ EVOQUE Valve Replacement System First Transcatheter Therapy to Earn FDA Approval for Tricuspid Valve
Halia Therapeutics Announces Collaboration with Canary Speech to Leverage its Cutting Edge AI- Driven Speech Technology to Advance the Clinical Development of Novel Therapeutics Targeting Neuroinflammation
This technology will support the development of Halia’s new Alzheimer’s disease drug, HT-4253, targeting a mediator of neuroinflammation called Leucine-rich repeat kinase 2 (LRRK2)
AdvaMed Announces New Chair of State Medtech Alliance
AdvaMed Announces New Chair of State Medtech Alliance
AI Utah Annouces Inaugural AI Utah 100 List
AI Utah Annouces Inaugural AI Utah 100 List
Myriad Genetics Completes Acquisition of Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics
Myriad Genetics Completes Acquisition of Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics
Inherent Biosciences and Genomic Prediction Announce Commercial Partnership to Advance Male Reproductive Health
Inherent Biosciences and Genomic Prediction Announce Commercial Partnership to Advance Male Reproductive Health
